omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
Company profile
Ticker
OMER
Exchange
Website
CEO
Gregory Demopulos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
911663741
OMER stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
1 Apr 24
8-K
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
1 Apr 24
8-K
Entry into a Material Definitive Agreement
7 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Omeros Corporation Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
16 Oct 23
S-8
Registration of securities for employees
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Omeros Corporation Reports Second Quarter 2023 Financial Results
9 Aug 23
8-K
Departure of Directors or Certain Officers
28 Jun 23
Transcripts
OMER
Earnings call transcript
2023 Q4
1 Apr 24
OMER
Earnings call transcript
2023 Q3
9 Nov 23
OMER
Earnings call transcript
2023 Q2
9 Aug 23
OMER
Earnings call transcript
2023 Q1
9 May 23
OMER
Earnings call transcript
2022 Q4
13 Mar 23
OMER
Earnings call transcript
2022 Q3
10 Nov 22
OMER
Earnings call transcript
2022 Q2
10 Aug 22
OMER
Earnings call transcript
2022 Q1
11 May 22
OMER
Earnings call transcript
2021 Q4
2 Mar 22
OMER
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
SC 13G/A
INGALLS & SNYDER LLC
27 Mar 24
SC 13G/A
Demopulos Gregory A MD
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
4
Gregory A MD Demopulos
21 Nov 23
4
Peter A MD Demopulos
17 Nov 23
4
Gregory A MD Demopulos
15 Nov 23
4
Gregory A MD Demopulos
27 Sep 23
4
MICHAEL A JACOBSEN
27 Sep 23
4
Peter B Cancelmo
27 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 30.64 mm | 30.64 mm | 30.64 mm | 30.64 mm | 30.64 mm | 30.64 mm |
Cash burn (monthly) | (no burn) | 9.57 mm | 16.05 mm | 13.74 mm | 10.88 mm | (no burn) |
Cash used (since last report) | n/a | 63.32 mm | 106.15 mm | 90.88 mm | 71.97 mm | n/a |
Cash remaining | n/a | -32.68 mm | -75.51 mm | -60.24 mm | -41.33 mm | n/a |
Runway (months of cash) | n/a | -3.4 | -4.7 | -4.4 | -3.8 | n/a |
Institutional ownership, Q3 2023
49.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 104 |
Opened positions | 13 |
Closed positions | 14 |
Increased positions | 33 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 64.70 bn |
Total shares | 28.75 mm |
Total puts | 462.00 k |
Total calls | 332.40 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
Ingalls & Snyder | 4.64 mm | $13.56 mm |
BLK Blackrock | 4.03 mm | $11.75 bn |
Vanguard | 3.14 mm | $9.18 bn |
RY Royal Bank Of Canada | 2.06 mm | $6.00 bn |
SF Stifel Financial | 2.03 mm | $5.92 bn |
D. E. Shaw & Co | 1.79 mm | $25.15 mm |
D. E. Shaw & Co. | 1.36 mm | $3.98 bn |
Geode Capital Management | 1.28 mm | $3.75 bn |
STT State Street | 1.16 mm | $3.39 bn |
CI Private Wealth | 686.91 k | $2.01 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Nov 23 | Gregory A Demopulos MD | Common Stock | Buy | Acquire P | Yes | No | 1.68 | 15,000 | 25.20 k | 123,945 |
15 Nov 23 | Demopulos Peter A MD | Common Stock | Buy | Acquire P | No | No | 1.53 | 10,000 | 15.30 k | 208,516 |
14 Nov 23 | Gregory A Demopulos MD | Common Stock | Grant | Acquire A | Yes | No | 1.44 | 25,000 | 36.00 k | 108,945 |
13 Nov 23 | Gregory A Demopulos MD | Common Stock | Grant | Acquire A | Yes | No | 1.29 | 37,500 | 48.38 k | 83,945 |
22 Sep 23 | Michael A Jacobsen | Stock Option Common Stock | Grant | Acquire A | No | No | 2.94 | 100,000 | 294.00 k | 100,000 |
22 Sep 23 | Peter B Cancelmo | Stock Option Common Stock | Grant | Acquire A | No | No | 2.94 | 100,000 | 294.00 k | 100,000 |
News
CORRECTION: Omeros Q4 EPS $(0.63) Misses $(0.55) Estimate
2 Apr 24
Omeros Q4 2023 GAAP EPS $(0.15) Beats $(0.56) Estimate
1 Apr 24
Earnings Scheduled For April 1, 2024
1 Apr 24
Investor Sentiment Edges Lower, US Stocks Record Gains Last Quarter
1 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
25 Mar 24